D2G Oncology, Inc.

D2G Oncology, Inc. is a biotechnology firm dedicated to developing innovative digital solutions that enhance cancer care and treatment through advanced data analytics and connectivity. Founded in 2018 and headquartered in Mountain View, US, D2G Oncology, Inc. specializes in leveraging cutting-edge technology to improve cancer treatment protocols.

The company has engaged in 1 deal, with their most recent financing being a Seed round, where they raised USD 6. 57 mn on February 12, 2020, bringing their total amount raised to USD 6. 57 mn and current valuation to USD 19. 00 mn.

The founder, Ian Winters, has a history in the biotech sector, contributing to advancements in healthcare technology. D2G Oncology, Inc. focuses on providing digital solutions aimed at enhancing cancer care, including data-driven platforms that support healthcare providers in making informed treatment decisions. Their offerings are designed to address challenges within oncology, providing tools that facilitate improved patient outcomes through better data management and accessibility.

These services are marketed primarily across North America and Europe, catering to healthcare institutions and providers seeking to optimize their oncology practices. The company generates revenue through a subscription model, allowing clients to access various tiers of its services based on their operational requirements. Clients typically engage in monthly or annual subscription agreements, selecting packages that meet their needs. Additionally, partnerships within the healthcare sector further bolster their revenue streams, promoting collaborative initiatives that enhance treatment efficacy in oncology.

Their flagship products aim to ensure comprehensive digital integration for healthcare providers, contributing to consistent revenue through B2B and direct-to-consumer transactions. Looking forward, D2G Oncology, Inc. is planning to introduce new digital health products designed to enhance data analytics capabilities for oncology care, with anticipated launches in the next 12 to 18 months. The company is also targeting expansion into European and Asian markets by 2022, aiming to increase their operational footprint and service reach.

The recent Seed funding of USD 6. 57 mn will primarily support these growth initiatives, enabling the development of new applications and facilitating market entry strategies.